CLINICAL VIEW ON SUBSTANCE-INDUCED PSYCHOTIC SYMPTOMS IN A MEDICALLY SUPERVISED INJECTING ROOM: A DECADE OF EXPERIENCE.

"CONFLICT OF INTERESTS Dr. Palma-Álvarez has received fees to give talks for Angelini, Exeltis, Lundbeck, MSD, Mundipharma, and Takeda. Dr. Roncero has received fees to give lectures for Janssen-Cilag, Ferrer-Brainfarma, Pfizer, Indivior, Lundbeck, Otsuka, Servier, GSK, Rovi, Astra, Gilead, MSD, Sanofi, and Exeltis. He has received financial compensation for his participation as a board member of JanssenCilag, Lundbeck, Gilead, MSD, Indivior, and Mundipharma. He has carried out the PROTEUS project, which was funded by a grant from Reckitt-Benckiser/Indivior. He received a medical education grant for Gilead. Dr. Ramos-Quiroga has received fees as speaker from Janssen-Cilag, Shire, Lilly, Ferrer, Medice, and Rubió. He has received research funding from Janssen-Cilag, Lilly, Ferrer, Lundbeck, and Rubió. Dr. Grau-López has received fees to give talks for Janssen-Cilag, Lundbeck, Servier, Otsuka, and Pfizer. The other authors have no competing conflicts of interest and report no financial relationships with commercial interests."

"FUNDINGThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for- profit sectors."